Official websites use .gov
A
.gov website belongs to an official government
organization in the United States.
Secure .gov websites use HTTPS
A
lock (
) or https:// means you’ve safely connected to
the .gov website. Share sensitive information only on official,
secure websites.
SCDTDP
93.365
The objectives of this project is to support the development and establishment of systemic mechanisms to improve the prevention and treatment of sickle cell disease complications, including the coordination of service delivery for individuals with sickle cell disease; genetic counseling and testing; bundling of technical services related to the prevention and treatment of sickle cell disease; training of health professionals; and identifying and establishing efforts related to the expansion and coordination of education, treatment, and continuity of care for individuals with Sickle Cell Disease as authorized in 42 USC Section 300b-5(b) (Section 1106(b) of the Public Health Service Act).
This chart shows obligations for the program by fiscal year. All data for this chart was provided by the
administering agency and sourced from SAM.gov, USASpending.gov, and Treasury.gov.
For more information on each of these data sources, please see the
About the data page.
In FY 20, The Sickle Cell Treatment Demonstration Program served more than 25,000 individuals living with Sickle Cell Disease across the United States.
Sickle Cell Treatment Demonstration Program served more than 25,000 individuals living with sickle cell disease(SCD) across the United States. Providers participating in the program prescribed hydroxyurea (a disease-modifying therapy) to 70% of their pediatric population and 14% of their pediatric population with other disease-modifying treatments. 57% of their adult patients received hydroxyurea prescriptions and 33% of their adult patients received other disease modifying therapy prescriptions. Furthermore, SCD providers indicated that 65% of eligible individuals with SCD (ages 2-16) had a transcranial doppler screening within the past 15 months, an important tool for detecting stroke risk which is elevated in individuals with SCD.
In FY 20, the Sickle Cell Treatment Demonstration Program served more than 25,000 individuals living with sickle cell disease(SCD) across the United States. Providers participating in the program prescribed hydroxyurea (a disease-modifying therapy) to 70% of their pediatric population and 14% of their pediatric population with other disease-modifying treatments. 57% of their adult patients received hydroxyurea prescriptions and 33% of their adult patients received other disease modifying therapy prescriptions. Furthermore, SCD providers indicated that 65% of eligible individuals with SCD (ages 2-16) had a transcranial doppler screening within the past 15 months, an important tool for detecting stroke risk which is elevated in individuals with SCD.
In FY 23, the Sickle Cell Treatment Demonstration Program served more than 25,000 individuals living with sickle cell disease (SCD) across the United States. Providers participating in the program prescribed disease-modifying therapies to more than 75% of their patient population. Furthermore, almost 3,800 providers participated in SCD-based Project ECHO sessions or telementoring calls, which helps expand the number of providers with improved SCD knowledge and care tools and resources.
Single Audit Applies (2 CFR Part 200 Subpart F):
For additional information on single audit requirements for this program, review the current Compliance Supplement.
OMB is working with the U.S. Government Accountability Office (GAO) and agency offices of inspectors general to include links to relevant oversight reports. This section will be updated once this information is made available.
